IL204804A - Purine history of pyrimidine is conserved - Google Patents

Purine history of pyrimidine is conserved

Info

Publication number
IL204804A
IL204804A IL204804A IL20480410A IL204804A IL 204804 A IL204804 A IL 204804A IL 204804 A IL204804 A IL 204804A IL 20480410 A IL20480410 A IL 20480410A IL 204804 A IL204804 A IL 204804A
Authority
IL
Israel
Prior art keywords
purine derivatives
substituted purine
pyrimidine substituted
pyrimidine
derivatives
Prior art date
Application number
IL204804A
Other languages
English (en)
Hebrew (he)
Other versions
IL204804A0 (en
Original Assignee
Verastem Inc
S Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc, S Bio Pte Ltd filed Critical Verastem Inc
Publication of IL204804A0 publication Critical patent/IL204804A0/en
Publication of IL204804A publication Critical patent/IL204804A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
IL204804A 2007-10-05 2010-03-28 Purine history of pyrimidine is conserved IL204804A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97772007P 2007-10-05 2007-10-05
US7553208P 2008-06-25 2008-06-25
PCT/SG2008/000379 WO2009045175A1 (en) 2007-10-05 2008-10-03 Pyrimidine substituted purine derivatives

Publications (2)

Publication Number Publication Date
IL204804A0 IL204804A0 (en) 2010-11-30
IL204804A true IL204804A (en) 2014-11-30

Family

ID=40030252

Family Applications (2)

Application Number Title Priority Date Filing Date
IL204804A IL204804A (en) 2007-10-05 2010-03-28 Purine history of pyrimidine is conserved
IL235555A IL235555B (en) 2007-10-05 2014-11-06 Methods for preparing pyrimidine-converted purine derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL235555A IL235555B (en) 2007-10-05 2014-11-06 Methods for preparing pyrimidine-converted purine derivatives

Country Status (16)

Country Link
US (3) US8247410B2 (enExample)
EP (1) EP2209786B1 (enExample)
JP (2) JP5479346B2 (enExample)
KR (3) KR20160116045A (enExample)
CN (2) CN104119336B (enExample)
AU (1) AU2008307798B2 (enExample)
BR (1) BRPI0817503B8 (enExample)
CA (1) CA2701581C (enExample)
DK (1) DK2209786T3 (enExample)
ES (1) ES2406129T3 (enExample)
IL (2) IL204804A (enExample)
MX (1) MX2010003668A (enExample)
MY (1) MY150993A (enExample)
RU (2) RU2681081C2 (enExample)
WO (1) WO2009045175A1 (enExample)
ZA (1) ZA201003118B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
DK2209786T3 (da) 2007-10-05 2013-06-03 Verastem Inc Pyrimidinsubstituerede purinderivater
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
JP2011527342A (ja) * 2008-07-07 2011-10-27 エックスカバリー ホールディング カンパニー エルエルシー Ｐｉ３ｋアイソフォーム選択的阻害剤
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
WO2010056320A2 (en) * 2008-11-11 2010-05-20 Tyrogenex, Inc. Pi3k/mtor kinase inhibitors
AU2010229468A1 (en) 2009-03-27 2011-10-13 Vetdc, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010114494A1 (en) * 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders
CN102428085B (zh) 2009-04-03 2015-07-15 维拉斯通股份有限公司 作为激酶抑制剂的嘧啶取代的嘌呤化合物
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
DE102009049679A1 (de) * 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011078795A1 (en) * 2009-12-21 2011-06-30 S*Bio Pte Ltd Bridged morpholino substituted purines
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
EP2691384B1 (en) 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
WO2012172043A1 (en) 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
JP2015500829A (ja) * 2011-12-05 2015-01-08 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉに対するｈｅｒ３の抗体
US9145411B2 (en) 2012-08-02 2015-09-29 Asana Biosciences, Llc Substituted amino-pyrimidine derivatives
WO2015055071A1 (zh) * 2013-10-16 2015-04-23 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
WO2016109426A1 (en) * 2014-12-29 2016-07-07 Verastem, Inc. Oral dosing regimen of a dual mtor and pi3 inhibitor
CN105985354B (zh) * 2015-02-09 2020-10-02 南京盖特医药技术有限公司 嘧啶衍生物、细胞毒性剂、药物组合物及其应用
EP3277682B1 (en) 2015-03-30 2019-04-24 Daiichi Sankyo Company, Limited 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors
KR101589900B1 (ko) 2015-07-30 2016-01-29 강영만 바닥설치용 경계구
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
TW201802093A (zh) * 2016-06-02 2018-01-16 西建公司 動物及人類抗錐蟲及抗利什曼原蟲藥劑
US20190263804A1 (en) * 2016-06-16 2019-08-29 Janssen Pharmaceutica Nv Azabenzimidazole derivatives as pi3k beta inhibitors
CN110036109A (zh) 2016-12-02 2019-07-19 第一三共株式会社 新颖的内-β-N-乙酰基氨基葡糖苷酶
EP3621604B1 (en) * 2017-03-31 2025-06-04 FTG Bio LLC Salt forms of amino pyrazine purine based selective kinase inhibitor
SI3609886T1 (sl) 2017-04-14 2024-05-31 Biogen Ma Inc. Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
WO2019036489A1 (en) 2017-08-14 2019-02-21 Mei Pharma, Inc. COMBINATION THERAPY
US11168072B2 (en) 2018-09-27 2021-11-09 Shanghai Yingli Pharmaceutical Co., Ltd Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
AU2019405925B2 (en) * 2018-12-20 2025-07-03 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors
ES3025474T3 (en) 2020-01-15 2025-06-09 Ksq Therapeutics Inc Compositions of substituted pyrazolopyrimidines and uses thereof
AU2021371305A1 (en) 2020-10-30 2023-06-15 KSQ Therapeutics, Inc. Solid state forms of substituted pyrazolopyrimidines and uses thereof
JP2024511996A (ja) * 2021-03-17 2024-03-18 タンゴ セラピューティクス， インコーポレイテッド 抗がん剤としてのプリン誘導体
AU2022407047A1 (en) * 2021-12-08 2024-07-25 Kineta, Inc. Bicyclic heteroarenes and methods of their use
CN118525011A (zh) * 2022-08-24 2024-08-20 上海璎黎药业有限公司 一种吗啉基喹唑啉类化合物、其制备方法及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617304A (en) 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
US4772606A (en) 1985-08-22 1988-09-20 Warner-Lambert Company Purine derivatives
DE122010000024I1 (de) * 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
UA62996C2 (en) * 1998-02-26 2004-01-15 Aventic Pharmaceuticals Inc 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
JP3810017B2 (ja) * 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
BR0112665A (pt) * 2000-07-19 2003-06-24 Novartis Ag Sais
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
EP1578722A4 (en) 2001-10-12 2006-09-06 Irm Llc KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
EP1551410A2 (en) 2002-09-06 2005-07-13 Smithkline Beecham Corporation Novel compounds
CA2502356A1 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
ATE527250T1 (de) * 2002-11-21 2011-10-15 Novartis Ag 2,4,6-trisubstituierten pyrimidinen als phosphotidylinositol (pi) 3-kinase inhibitoren und deren verwendung zur behandlung von krebs
SI2316831T1 (sl) * 2002-11-21 2013-07-31 Novartis Ag 2-(morfolin-4-il)pirimidini kot inhibitorji fosfotidilinozitol (PI) 3-kinaze in njihova uporaba pri zdravljenju raka
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
US8071609B2 (en) 2005-08-11 2011-12-06 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
GB0519245D0 (en) 2005-09-20 2005-10-26 Vernalis R&D Ltd Purine compounds
CL2007002866A1 (es) 2006-10-04 2008-07-04 Pharmacopeia Inc Compuestos derivados de 6-sustituidos-2-(bencimidazolil) purina y purinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades autoinmunes, enfermedad inflamatoria, enfermedad mediada por m
US7902187B2 (en) * 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
US20080233127A1 (en) 2007-03-21 2008-09-25 Wyeth Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2009045174A1 (en) 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
DK2209786T3 (da) 2007-10-05 2013-06-03 Verastem Inc Pyrimidinsubstituerede purinderivater
TW200938201A (en) 2008-02-07 2009-09-16 Chugai Pharmaceutical Co Ltd Pyrrolopyrimidine derivative as PI3K inhibitor and use thereof
US8158624B2 (en) 2008-05-30 2012-04-17 Genetech, Inc. Purine PI3K inhibitor compounds and methods of use
US20110105500A1 (en) 2008-06-27 2011-05-05 S*Bio Pte Ltd. Pyrazine substituted purines
JP2011527342A (ja) 2008-07-07 2011-10-27 エックスカバリー ホールディング カンパニー エルエルシー Ｐｉ３ｋアイソフォーム選択的阻害剤
CN102428085B (zh) 2009-04-03 2015-07-15 维拉斯通股份有限公司 作为激酶抑制剂的嘧啶取代的嘌呤化合物
WO2010114494A1 (en) 2009-04-03 2010-10-07 S*Bio Pte Ltd 8-substituted-2-morpholino purines for use as pi3k and/or mtor inhibitors in the treatment of proliferative disorders

Also Published As

Publication number Publication date
RU2681081C2 (ru) 2019-03-04
JP2014139159A (ja) 2014-07-31
US8609838B2 (en) 2013-12-17
AU2008307798A1 (en) 2009-04-09
CA2701581A1 (en) 2009-04-09
MY150993A (en) 2014-03-31
JP5479346B2 (ja) 2014-04-23
ZA201003118B (en) 2011-08-31
HK1145832A1 (en) 2011-05-06
KR101643237B1 (ko) 2016-07-27
JP2010540625A (ja) 2010-12-24
KR20150063171A (ko) 2015-06-08
IL235555B (en) 2019-08-29
IL235555A0 (en) 2014-12-31
BRPI0817503A2 (pt) 2015-05-05
CN101889015A (zh) 2010-11-17
CN104119336B (zh) 2016-08-24
RU2010117737A (ru) 2011-11-10
US8247410B2 (en) 2012-08-21
KR20160116045A (ko) 2016-10-06
MX2010003668A (es) 2010-07-02
BRPI0817503B1 (pt) 2019-10-29
CA2701581C (en) 2016-12-20
US20130079512A1 (en) 2013-03-28
JP5885729B2 (ja) 2016-03-15
WO2009045175A1 (en) 2009-04-09
CN104119336A (zh) 2014-10-29
EP2209786A1 (en) 2010-07-28
RU2518098C2 (ru) 2014-06-10
ES2406129T3 (es) 2013-06-05
KR20100075609A (ko) 2010-07-02
IL204804A0 (en) 2010-11-30
KR101701109B1 (ko) 2017-02-13
CN101889015B (zh) 2014-06-04
RU2014110894A (ru) 2015-07-10
US20140066620A1 (en) 2014-03-06
AU2008307798B2 (en) 2013-10-03
EP2209786B1 (en) 2013-02-27
HK1203488A1 (en) 2015-10-30
DK2209786T3 (da) 2013-06-03
BRPI0817503B8 (pt) 2021-05-25
US20100298319A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
IL235555A0 (en) A purine is converted to a pyrimidine
PL2154967T3 (pl) Pochodne pirymidyny
IL205425A0 (en) Novel pyrimidine derivatives
ZA200806153B (en) Pyrimidine derivatives
IL210176A0 (en) Substituted pyrimidone derivatives
PL2125792T3 (pl) Pochodne puryny jako immunomodulatory
GB0706632D0 (en) New purine derivatives
IL210855A (en) Annals of Adenine
IL210124A0 (en) Pyrimidine derivatives as kinase inhibitors
ZA200805294B (en) Pyrimidine derivatives
IL205625A0 (en) Antiviral nucleoside compounds
GB0614579D0 (en) Pyrimidine derivatives
ZA201006104B (en) Substituted xanthine derivatives
IL210172A0 (en) Substituted pyrimidin-4-one derivatives
ZA201000107B (en) Pyrimidine derivatives 934
GB0525080D0 (en) Pyrimidine derivatives
IL195018A0 (en) Piperidinyl pyrimidine derivatives
GB0525083D0 (en) Pyrimidine derivatives
EP2061470A4 (en) HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES
EP2094704A4 (en) CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES
IL201249A (en) Polates marked f 18
GB0525081D0 (en) Pyrimidine derivatives
ZA201102607B (en) Heterocyclic antiviral arylpyridone derivatives
HK1147485A (en) Novel pyrimidine derivatives

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed